Can a confirmed high-risk paraneoplastic antibody justify a malignancy search even if cancer is not yet evident?

A high-risk paraneoplastic antibody is an important cancer-risk signal in suspected paraneoplastic neurologic syndrome (PNS), particularly in an older adult, but must be interpreted alongside the neurologic syndrome, assay confirmation, and imaging findings.

Clinical evidence

• Consensus PNS-Care guidance supports prompt, phenotype- and antibody-directed malignancy screening without waiting for a tumor to become clinically apparent.
• Initial evaluation generally includes contrast-enhanced CT of the chest, abdomen, and pelvis, with tumor-specific testing as indicated; whole-body FDG-PET/CT is appropriate when conventional imaging is unrevealing but suspicion remains high.
• If a compatible high-risk neurologic phenotype accompanies a confirmed high-risk antibody and initial screening is negative, repeat screening every 4–6 months for 2 years is recommended.
• Relevant associations guide targeted searching: Yo/PCA1 with breast or ovarian cancer; CV2/CRMP5 with small-cell lung cancer or thymoma; and amphiphysin with breast, small-cell lung, or ovarian cancer.

Interpreting antibody positivity

• High-risk antibodies have a cancer association exceeding 70% in the PNS-Care classification. This is a strong association, not proof that a particular individual currently has an occult tumor.
• Individual probability depends on the phenotype, specific antibody, baseline cancer risk, testing method, and whether the finding is corroborated in serum and cerebrospinal fluid.
• Analytical confirmation matters: commercial line-blot results can be false positive and should be supported by tissue-based and antigen-specific testing. For example, line-blot-only SOX1 positivity was not a reliable cancer predictor, whereas tissue- and cell-based assay-confirmed cases were associated with lung cancer.

Bottom line

• A confirmed high-risk paraneoplastic antibody can justify urgent, targeted cancer evaluation—and risk-adapted repeat surveillance despite initially negative imaging—but it does not alone establish that occult cancer is present.